Base de dados : MEDLINE
Pesquisa : C16.320.565.398.493 [Categoria DeCS]
Referências encontradas : 241 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 25 ir para página                         

  1 / 241 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27914033
[Au] Autor:Florentin M; Elisaf MS; Rizos CV; Nikolaou V; Bilianou E; Pitsavos C; Liberopoulos EN
[Ad] Endereço:Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.
[Ti] Título:L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.
[So] Source:Lipids;52(1):1-9, 2017 Jan.
[Is] ISSN:1558-9307
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. There are currently limited therapeutic options to lower Lp(a) levels. L-Carnitine has been reported to reduce Lp(a) levels. The aim of this study was to compare the effect of L-carnitine/simvastatin co-administration with that of simvastatin monotherapy on Lp(a) levels in subjects with mixed hyperlipidemia and elevated Lp(a) concentration. Subjects with levels of low-density lipoprotein cholesterol (LDL-C) >160 mg/dL, triacylglycerol (TAG) >150 mg/dL and Lp(a) >20 mg/dL were included in this study. Subjects were randomly allocated to receive L-carnitine 2 g/day plus simvastatin 20 mg/day (N = 29) or placebo plus simvastatin 20 mg/day (N = 29) for a total of 12 weeks. Lp(a) was significantly reduced in the L-carnitine/simvastatin group [-19.4%, from 52 (20-171) to 42 (15-102) mg/dL; p = 0.01], but not in the placebo/simvastatin group [-6.7%, from 56 (26-108) to 52 (27-93) mg/dL, p = NS versus baseline and p = 0.016 for the comparison between groups]. Similar significant reductions in total cholesterol, LDL-C, apolipoprotein (apo) B and TAG were observed in both groups. Co-administration of L-carnitine with simvastatin was associated with a significant, albeit modest, reduction in Lp(a) compared with simvastatin monotherapy in subjects with mixed hyperlipidemia and elevated baseline Lp(a) levels.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Carnitina/administração & dosagem
Hiperlipoproteinemia Tipo V/tratamento farmacológico
Lipoproteína(a)/metabolismo
Sinvastatina/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Apolipoproteína B-100/metabolismo
Doenças Cardiovasculares/metabolismo
Carnitina/farmacologia
Colesterol/sangue
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Hiperlipoproteinemia Tipo V/metabolismo
Masculino
Meia-Idade
Estudos Prospectivos
Sinvastatina/farmacologia
Resultado do Tratamento
Triglicerídeos/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (APOB protein, human); 0 (Apolipoprotein B-100); 0 (Lipoprotein(a)); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol); AGG2FN16EV (Simvastatin); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171105
[Lr] Data última revisão:
171105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161204
[St] Status:MEDLINE
[do] DOI:10.1007/s11745-016-4216-z


  2 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26626968
[Au] Autor:Russi G
[Ad] Endereço:Transfusion Medicine Unit, IRCCS - Arcispedale Santa Maria Nuova, Viale Risorgimento 80, 42123 Reggio Emilia (RE), Italy. Electronic address: gianpaolo.russi@asmn.re.it.
[Ti] Título:Severe dyslipidemia in pregnancy: The role of therapeutic apheresis.
[So] Source:Transfus Apher Sci;53(3):283-7, 2015 Dec.
[Is] ISSN:1473-0502
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:During pregnancy physiological changes occur in the lipid metabolism due to changing hormonal conditions: the LDL cholesterol (LDL-C), triglycerides (TG) and lipoprotein(a) [Lp(a)] increase throughout pregnancy. Common lipoprotein disorders are associated in pregnancy with two major clinical disorders: severe hypertriglyceridemia (SHTG) is a potent risk factor for development of acute pancreatitis and elevated cholesterol due to greater concentrations of LDL and remnant lipoproteins and reduced levels of HDL promote atherosclerosis. The combination of homozygous Familial Hypercholesterolemia (HoFH) and pregnancy can be a fatal condition. Therapeutic plasma exchange (TPE) may be used for an urgent need of a fast and effective lowering of TG levels in order to prevent a severe pancreatitis episode or hypertriglyceridemia-induced complications during pregnancy. LDL apheresis can decrease LDL-C and prevent complications and can be considered in the treatment of pregnancies complicated by high LDL-C. These conditions are configured in patients with HeFH who were taking statins before pregnancy (selected cases), patients already receiving apheresis before pregnancy suffering from HoFH, patients suffering from hypertriglyceridemia due to familial hyperlipoproteinemia types I and V, and cases of hypertriglyceridemia secondary to diabetes.
[Mh] Termos MeSH primário: Remoção de Componentes Sanguíneos/métodos
Hiperlipoproteinemia Tipo II/terapia
Hiperlipoproteinemia Tipo I/terapia
Hiperlipoproteinemia Tipo V/terapia
Hipertrigliceridemia/terapia
Troca Plasmática/métodos
Complicações na Gravidez/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Hiperlipoproteinemia Tipo I/sangue
Hiperlipoproteinemia Tipo II/sangue
Hiperlipoproteinemia Tipo V/sangue
Hipertrigliceridemia/sangue
Lipídeos/sangue
Gravidez
Complicações na Gravidez/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Lipids)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:151203
[St] Status:MEDLINE


  3 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25732519
[Au] Autor:Brahm AJ; Hegele RA
[Ad] Endereço:Department of Medicine, Schulich School of Medicine and Dentistry, Western University, 4288A-1151 Richmond Street North, London, ON N6A 5B7, Canada.
[Ti] Título:Chylomicronaemia--current diagnosis and future therapies.
[So] Source:Nat Rev Endocrinol;11(6):352-62, 2015 Jun.
[Is] ISSN:1759-5037
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This Review discusses new developments in understanding the basis of chylomicronaemia--a challenging metabolic disorder for which there is an unmet clinical need. Chylomicronaemia presents in two distinct primary forms. The first form is very rare monogenic early-onset chylomicronaemia, which presents in childhood or adolescence and is often caused by homozygous mutations in the gene encoding lipoprotein lipase (LPL), its cofactors apolipoprotein C-II or apolipoprotein A-V, the LPL chaperone lipase maturation factor 1 or glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1. The second form, polygenic late-onset chylomicronaemia, which is caused by an accumulation of several genetic variants, can be exacerbated by secondary factors, such as poor diet, obesity, alcohol intake and uncontrolled type 1 or type 2 diabetes mellitus, and is more common than early-onset chylomicronaemia. Both forms of chylomicronaemia are associated with an increased risk of life-threatening pancreatitis; the polygenic form might also be associated with an increased risk of cardiovascular disease. Treatment of chylomicronaemia focuses on restriction of dietary fat and control of secondary factors, as available pharmacological therapies are only minimally effective. Emerging therapies that might prove more effective than existing agents include LPL gene therapy, inhibition of microsomal triglyceride transfer protein and diacylglycerol O-acyltransferase 1, and interference with the production and secretion of apoC-III and angiopoietin-like protein 3.
[Mh] Termos MeSH primário: Dietoterapia
Hiperlipoproteinemia Tipo I/diagnóstico
Hiperlipoproteinemia Tipo I/terapia
Hiperlipoproteinemia Tipo V/terapia
Hipolipemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Benzimidazóis/uso terapêutico
Ácidos Fíbricos/uso terapêutico
Terapia Genética
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hiperlipoproteinemia Tipo I/genética
Hiperlipoproteinemia Tipo V/diagnóstico
Niacina/uso terapêutico
Troca Plasmática
Plasmaferese
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (BMS201038); 0 (Benzimidazoles); 0 (Fibric Acids); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypolipidemic Agents); 2679MF687A (Niacin)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150304
[St] Status:MEDLINE
[do] DOI:10.1038/nrendo.2015.26


  4 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24890424
[Au] Autor:Cohen M; Kedia P; Sharaiha R; Kahaleh M
[Ad] Endereço:Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA.
[Ti] Título:Tamponade of a bleeding pseudocyst with a fully covered metal stent.
[So] Source:Gastrointest Endosc;81(1):229-30, 2015 Jan.
[Is] ISSN:1097-6779
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hemorragia/cirurgia
Hemostase Endoscópica/métodos
Pseudocisto Pancreático/cirurgia
Pancreatite Necrosante Aguda/cirurgia
Stents
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Hiperlipoproteinemia Tipo V/complicações
Masculino
Metais
Pancreatopatias/cirurgia
Pseudocisto Pancreático/etiologia
Pancreatite Necrosante Aguda/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Metals)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141220
[Lr] Data última revisão:
141220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140604
[St] Status:MEDLINE


  5 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25043541
[Au] Autor:Díaz Rodríguez Á
[Ad] Endereço:Medicina Familiar y Comunitaria, Centro de Salud de Bembibre, León, España. Electronic address: med015917@yahoo.es.
[Ti] Título:[The fixed combination of pravastatin and fenofibrate: what can it provide?].
[Ti] Título:Combinación fija pravastatina/fenofibrato: ¿qué puede aportar?.
[So] Source:Clin Investig Arterioscler;26 Suppl 1:12-6, 2014 Jul.
[Is] ISSN:1578-1879
[Cp] País de publicação:Spain
[La] Idioma:spa
[Ab] Resumo:The treatment of patients with high cardiovascular risk and mixed hyperlipidemia is difficult due to multiple quantitative and qualitative lipid abnormalities. The priority is to reduce LDL-c levels, for which statins are the drug of choice. Despite the benefits of statins, the residual cardiovascular risk is very high in patients with atherogenic dyslipidemia. To reduce this risk, we also need to control non-HDL cholesterol levels, decreasing triglyceride levels and increasing HDL-c levels. To achieve these objectives and lifestyle changes, the use of combined therapy is often required. Fibrates are drugs that can be used in combination with statins to reduce this residual risk. Fenofibrate is well tolerated in combination with statins. The fixed combination of pravastatin/ fenofibrate has been shown to have complementary benefits in the atherogenic lipid profile in general. The combination is well tolerated and is indicated in patients with high risk and mixed hyperlipidemia who have controlled or are close to their objectives for LDL-c levels, using 40-mg pravastatin in monotherapy. The beneficial eff ect of the combination on LDL-c levels is minimal and is primarily observed in non-HDL cholesterol, triglycerides and HDL-c. The combination of pravastatin 40 and fenofibrate 160 can provide a considerable clinical benefit to patients with high risk and mixed atherogenic dyslipidemia, to patients with LDL-c levels that are controlled or near the objectives for decreasing their residual risk of lipid origin and is especially useful for patients with type 2 diabetes, obesity and combined metabolic syndrome and familial hyperlipidemia.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Dislipidemias/tratamento farmacológico
Fenofibrato/administração & dosagem
Pravastatina/administração & dosagem
[Mh] Termos MeSH secundário: Aterosclerose/etiologia
Aterosclerose/prevenção & controle
Doenças Cardiovasculares/etiologia
Combinação de Medicamentos
Dislipidemias/complicações
Fenofibrato/efeitos adversos
Fenofibrato/uso terapêutico
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hiperlipoproteinemia Tipo V/complicações
Hiperlipoproteinemia Tipo V/tratamento farmacológico
Hipolipemiantes/administração & dosagem
Hipolipemiantes/efeitos adversos
Hipolipemiantes/uso terapêutico
Pravastatina/efeitos adversos
Pravastatina/uso terapêutico
Fatores de Risco
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypolipidemic Agents); KXO2KT9N0G (Pravastatin); U202363UOS (Fenofibrate)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:140721
[Lr] Data última revisão:
140721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140722
[St] Status:MEDLINE


  6 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24006596
[Au] Autor:Müller-Edenborn B; Kenngott S; Müller D; Magdeburg B
[Ad] Endereço:Abteilung für Innere Medizin/Gastroenterologle, GZO Spital Wetzikon. bjoern.mueller-edenborn@access.uzh
[Ti] Título:[Type V hyperlipidemia--an uncommon cause for pancreatitis].
[Ti] Título:Das Labor weist den Weg. Keine Gallensteine, wenig Alkohol--wie kam es zu dieser Pankreatitis?.
[So] Source:MMW Fortschr Med;155(14):48-9, 2013 Aug 22.
[Is] ISSN:1438-3276
[Cp] País de publicação:Germany
[La] Idioma:ger
[Mh] Termos MeSH primário: Hiperlipoproteinemia Tipo V/diagnóstico
Pancreatite/etiologia
Triglicerídeos/sangue
[Mh] Termos MeSH secundário: Doença Aguda
Diagnóstico Diferencial
Eletroforese
Feminino
Cálculos Biliares/diagnóstico
Seres Humanos
Hiperlipoproteinemia Tipo V/sangue
Hiperlipoproteinemia Tipo V/complicações
Hiperlipoproteinemia Tipo V/terapia
Meia-Idade
Pancreatite/sangue
Pancreatite/terapia
Pancreatite Alcoólica/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Triglycerides)
[Em] Mês de entrada:1311
[Cu] Atualização por classe:140110
[Lr] Data última revisão:
140110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130907
[St] Status:MEDLINE


  7 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23428107
[Au] Autor:Gaudet D; Signorovitch J; Swallow E; Fan L; Tremblay K; Brisson D; Meyers C; Gruenberger JB
[Ad] Endereço:Ecogene-21 Clinical Research Center and Department of Medicine, Université de Montréal, Montreal, Canada. daniel.gaudet@umontreal.ca
[Ti] Título:Medical resource use and costs associated with chylomicronemia.
[So] Source:J Med Econ;16(5):657-66, 2013.
[Is] ISSN:1941-837X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The prevalence of severe hypertriglyceridemia (TG > 1000 mg/dl) is estimated at 150-400 per 100,000 individuals in North America. Severe hypertriglyceridemia in the fasting state is associated with increased acute pancreatitis risk and is a sign of chylomicronemia which reflects the accumulation in the bloodstream of chylomicrons, the large lipoprotein particles produced in the gut after a meal. OBJECTIVE: To assess medical resource use and costs associated with chylomicronemia. METHODS: Patients with chylomicronemia of different causes (≥2 diagnoses with ICD-9 code 272.3) were identified from a large US claims database (years 2000 to 2009) and matched 1:1 to controls free of chylomicronemia based on age, gender, demographics, comorbidities, and use of lipid lowering drugs. During a 1-year study period, medical resource use and costs associated with chylomicronemia or acute pancreatitis were compared between matched cases and controls. RESULTS: Among 6472 matched pairs, annual per-patient medical costs, calculated independently of the occurrence of acute pancreatitis, were significantly greater by $808 for chylomicronemia cases vs controls ($8029 vs $7220, p < 0.01), half of which was attributable to chylomicronemia-related services (p < 0.01). Chylomicronemia cases with a history of acute pancreatitis (n = 46) had greater rates of inpatient visits (p < 0.05) and greater average costs for subsequent acute pancreatitis or abdominal pain (p < 0.01) as well as greater total medical costs ($33,587 vs $4402, p < 0.01) vs matched controls. The average episode of acute pancreatitis (n = 104 episodes) generated medical costs of $31,820, almost entirely due to inpatient stays. LIMITATIONS: Triglyceride levels were not available to characterize disease severity. CONCLUSIONS: Patients with chylomicronemia, and especially those with a history of acute pancreatitis, incurred significantly greater total medical costs compared with individuals without chylomicronemia but with an otherwise comparable health profile.
[Mh] Termos MeSH primário: Gastos em Saúde/estatística & dados numéricos
Hiperlipoproteinemia Tipo V/complicações
Hiperlipoproteinemia Tipo V/economia
Pancreatite/economia
Pancreatite/etiologia
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Fatores Etários
Idoso
Feminino
Serviços de Saúde/economia
Serviços de Saúde/utilização
Seres Humanos
Hiperlipoproteinemia Tipo V/tratamento farmacológico
Hipolipemiantes/uso terapêutico
Revisão da Utilização de Seguros
Masculino
Meia-Idade
Pancreatite/induzido quimicamente
Gravidade do Paciente
Fatores Sexuais
Fatores Socioeconômicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hypolipidemic Agents)
[Em] Mês de entrada:1311
[Cu] Atualização por classe:140731
[Lr] Data última revisão:
140731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130223
[St] Status:MEDLINE
[do] DOI:10.3111/13696998.2013.779277


  8 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22943927
[Au] Autor:Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
[Ad] Endereço:Department of Internal Medicine and Clinical Pharmacology, Silesian Medical University, Medykow 18, 40-752 Katowice, Poland. lbuldak@gmail.com
[Ti] Título:Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
[So] Source:Int J Clin Pharmacol Ther;50(11):805-13, 2012 Nov.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Concerns regarding worsening insulin sensitivity associated with statin treatment have recently emerged. Therefore the aim of this study was to assess and compare the effects of 90-day monotherapies with fenofibrate and atorvastatin, as well as combined therapy, on fasting plasma glucose, insulin resistance index, adipokines (leptin, resistin, adiponectin) and levels of proinflammatory cytokines (TNF-α, IL-6) in patients with impaired fasting glucose (IFG) and mixed hyperlipidemia. MATERIALS AND METHODS: 67 patients were randomly assigned to four treatment arms: monotherapy with atorvastatin, monotherapy with fenofibrate, combined therapy (fenofibrate and torvastatin) or therapeutic lifestyle change. The study lasted for 90 days. All participants received counseling regarding proper diet and physical activity. RESULTS: Compared to the control subjects, prediabetic patients exhibited elevated plasma levels of leptin, resistin, TNF-α and IL-6, and a lower plasma level of adiponectin. All therapeutic interventions resulted in significant alterations in the lipid profile. Insulin resistance index (HOMA-IR) was reduced after treatment with fenofibrate. The effect of atorvastatin on insulin resistance was comparable to therapeutic lifestyle change alone. Therapy with hypolipidemic drugs caused increases in adiponectin levels and decreases in leptin and resistin. An additive effect of the combined treatment on plasma IL-6 level was also observed. CONCLUSIONS: Fenofibrate-based treatment was associated with improved insulin sensitivity. Atorvastatin did not cause a deterioration in insulin sensitivity. Hypolipidemic therapies resulted in significant changes in the proinflammatory cytokine network as well as in adipokine levels. At the end of the study the measured parameters nearly resembled those of the healthy subjects.
[Mh] Termos MeSH primário: Adipocinas/sangue
Glicemia/efeitos dos fármacos
Citocinas/sangue
Fenofibrato/uso terapêutico
Transtornos do Metabolismo de Glucose/tratamento farmacológico
Ácidos Heptanoicos/uso terapêutico
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hiperlipoproteinemia Tipo V/tratamento farmacológico
Hipolipemiantes/uso terapêutico
Mediadores da Inflamação/sangue
Resistência à Insulina
Pirróis/uso terapêutico
[Mh] Termos MeSH secundário: Adiponectina/sangue
Adulto
Idoso
Análise de Variância
Atorvastatina Cálcica
Biomarcadores/sangue
Glicemia/metabolismo
Quimioterapia Combinada
Feminino
Transtornos do Metabolismo de Glucose/sangue
Transtornos do Metabolismo de Glucose/diagnóstico
Transtornos do Metabolismo de Glucose/imunologia
Seres Humanos
Hiperlipoproteinemia Tipo V/sangue
Hiperlipoproteinemia Tipo V/diagnóstico
Hiperlipoproteinemia Tipo V/imunologia
Insulina/sangue
Interleucina-6/sangue
Leptina/sangue
Lipídeos/sangue
Masculino
Meia-Idade
Polônia
Resistina/sangue
Comportamento de Redução do Risco
Fatores de Tempo
Resultado do Tratamento
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (ADIPOQ protein, human); 0 (Adipokines); 0 (Adiponectin); 0 (Biomarkers); 0 (Blood Glucose); 0 (Cytokines); 0 (Heptanoic Acids); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypolipidemic Agents); 0 (IL6 protein, human); 0 (Inflammation Mediators); 0 (Insulin); 0 (Interleukin-6); 0 (Leptin); 0 (Lipids); 0 (Pyrroles); 0 (RETN protein, human); 0 (Resistin); 0 (Tumor Necrosis Factor-alpha); 48A5M73Z4Q (Atorvastatin Calcium); U202363UOS (Fenofibrate)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120905
[St] Status:MEDLINE
[do] DOI:10.5414/CP201735


  9 / 241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22393551
[Au] Autor:Rehman HU
[Ad] Endereço:Department of Medicine, Regina Qu'Appelle Health Region, Regina General Hospital, Canada. habib31@sasktel.net
[Ti] Título:The work-up for mixed hyperlipidemia: a case study.
[So] Source:J Fam Pract;61(3):133-6, 2012 Mar.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This case demonstrates that a history, physical exam, and laboratory studies are all needed to determine if the disorder is primary, secondary, or both.
[Mh] Termos MeSH primário: Hiperlipoproteinemia Tipo V/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Colesterol/sangue
HDL-Colesterol/sangue
Diabetes Mellitus Tipo 2/complicações
Eletroforese
Fenofibrato/uso terapêutico
Fluorbenzenos/uso terapêutico
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hiperlipoproteinemia Tipo V/complicações
Hiperlipoproteinemia Tipo V/tratamento farmacológico
Hipertensão/complicações
Hipoglicemiantes/uso terapêutico
Hipolipemiantes/uso terapêutico
Lipoproteínas/metabolismo
Masculino
Metformina/uso terapêutico
Exame Físico
Pirimidinas/uso terapêutico
Rosuvastatina Cálcica
Sulfonamidas/uso terapêutico
Triglicerídeos/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol, HDL); 0 (Fluorobenzenes); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypoglycemic Agents); 0 (Hypolipidemic Agents); 0 (Lipoproteins); 0 (Pyrimidines); 0 (Sulfonamides); 0 (Triglycerides); 83MVU38M7Q (Rosuvastatin Calcium); 9100L32L2N (Metformin); 97C5T2UQ7J (Cholesterol); U202363UOS (Fenofibrate)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:120307
[St] Status:MEDLINE


  10 / 241 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:22129523
[Au] Autor:Gotoda T; Shirai K; Ohta T; Kobayashi J; Yokoyama S; Oikawa S; Bujo H; Ishibashi S; Arai H; Yamashita S; Harada-Shiba M; Eto M; Hayashi T; Sone H; Suzuki H; Yamada N; Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan
[Ad] Endereço:Department of Clinical and Molecular Epidemiology, 22nd Century Medical and Research Center, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan. gotoda-tky@umin.ac.jp
[Ti] Título:Diagnosis and management of type I and type V hyperlipoproteinemia.
[So] Source:J Atheroscler Thromb;19(1):1-12, 2012.
[Is] ISSN:1880-3873
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein lipase (LPL)- apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.
[Mh] Termos MeSH primário: Gerenciamento Clínico
Hiperlipoproteinemia Tipo I/diagnóstico
Hiperlipoproteinemia Tipo I/terapia
Hiperlipoproteinemia Tipo V/diagnóstico
Hiperlipoproteinemia Tipo V/terapia
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Seres Humanos
Lipase Lipoproteica/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
EC 3.1.1.34 (Lipoprotein Lipase)
[Em] Mês de entrada:1206
[Cu] Atualização por classe:120201
[Lr] Data última revisão:
120201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111202
[St] Status:MEDLINE



página 1 de 25 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde